Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 2/20 | 0.38 |
| ▸ | ADH1A | P07327 | 2/20 | 0.38 |
| ▸ | ADH4 | P08319 | 2/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.37 |
| ▸ | ADH7 | P40394 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95388 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL5469943 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL5479568 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL276847 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL277586 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL5480820 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL11667597 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL102599 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL276870 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL5477937 | 1.00 | DNM1 (0.48) | DNM1TSHRTHRBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8809348-B2 | 6-arylmethyl substituted pyrazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| EP-1697309-B1 | BENZOYL-SUBSTITUTED PHENYLALANINE AMIDES | BASF SE (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-8642605-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8603975-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-1888509-B1 | BENZOYL-SUBSTITUTED SERINE AMIDES | BASF SE (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120258964-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2012-10-11 | — | — | US | disclosed |
| US-8133851-B2 | Heteroaroyl-substituted serine amides | BASF SE (DE) | 2012-03-13 | — | — | US | disclosed |
| US-20120010224-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20110318470-A1 | Method For Improving Plant Health | BASF SE (DE) | 2011-12-29 | — | — | US | disclosed |
| US-4985444-A | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0379979-A1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-01 | — | — | EP | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318470-A1 | Method For Improving Plant Health | BROX, PAH, GUSB | DNM1 1420/4885TSHR 4140/4885THRB 2642/4885 |
| US-20140350008-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | DNM1 585/4885TSHR 4355/4885THRB 3510/4885 |
| US-20120258964-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | DNM1 585/4885TSHR 4355/4885THRB 3510/4885 |
| US-20120010224-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | GRM6, P2RX6, P2RY6 | DNM1 2501/4885TSHR 3828/4885THRB 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.